Apten, a subsidiary of Aprostegen, is advancing its blood cancer treatment GPC-100 toward a United States Phase 3 clinical trial and formal product approval, according to company announcements. The drug acts as a mobilization agent to move hematopoietic stem cells and immune cells into peripheral blood, and it holds orphan drug designation from the U.S. Food and Drug Administration (FDA).
Apten Advances GPC-100 Toward U.S. Phase 3 Trials
Phase 2 Results and FDA Protocol Plans
Apten plans to finalize a Phase 3 clinical protocol in consultation with the FDA, building directly on the results of a completed U.S. Phase 2 trial. According to company disclosures, GPC-100 demonstrated an ability to accelerate cell mobilization significantly faster than standard alternatives.
A similar drug in the same class, Motixafortide, secured FDA approval in September 2023 following a single Phase 3 clinical trial involving 122 patients, according to regulatory filings.
Overcoming Speed Limitations in Stem Cell Mobilization
Apten is initially targeting the blood cancer market for stem cell mobilization, where combination treatments are increasingly necessary. While multiple myeloma treatments like Darzalex—commercially known as daratumumab—have seen surging prescriptions, the drug frequently binds to stem cells and white blood cells, which slows their migration.
According to Apten, standard mobilization agents require 10 to 14 hours to take effect, limiting their utility in fast-paced clinical workflows. In contrast, company representatives state that GPC-100 operates in under one hour, a performance benchmark established during the U.S. Phase 2 evaluation.
Commercial Landscape and Licensing Valuations
Market valuations for competing therapies underscore the commercial landscape. Following its approval, Motixafortide licensing rights were split between Guangzhou Gloria Biosciences for Asia and Aermed for territories outside Asia, in a deal featuring a 3억5800만달러 upfront payment and a 23% royalty on net sales. Meanwhile, global market projections place Darzalex sales at 97억4400만달러, driving intense demand for compatible adjunctive therapies.
Expansion into Cellular and Gene Therapy Platforms
Beyond traditional oncology support, Apten is positioning GPC-100 as a booster platform for advanced treatments like in vivo CAR-T cell therapy. By rapidly increasing immune and stem cell counts in the bloodstream within a one-hour window post-administration—a capability observed in animal studies and Phase 2 trials—the asset aims to enhance manufacturing and therapeutic efficiency.
Company officials stated that the broad applicability of GPC-100 across both standard mobilization and cellular therapy sectors is expected to drive corporate valuation as late-stage trials begin.